2013-04-02 15:05:56 -
New System Designed for Patient Safety, Ease of Use During Open-Heart Procedures
MINNEAPOLIS - April 2, 2013 - Medtronic, Inc. (NYSE: MDT) today announced U.S.
Food and Drug Administration (FDA) 510(k) clearance and the first U.S. clinical
uses of its new Affinity Fusion(®) oxygenation system. This system, which is
designed to serve as a patient's lungs by oxygenating and removing carbon
dioxide from blood during various open-heart surgical procedures, incorporates
numerous innovations for patient safety and ease of use. Notably, system
enhancements are designed to prevent and remove air bubbles that can enter the
blood during the procedure, which may potentially reduce the risk of stroke.
The Affinity Fusion oxygenation system's new design enhancements include:
* A proprietary fiber winding process with an interlaced pattern that
efficiently filters the blood and removes particles and air while at the
same time oxygenating the blood;
* Smooth tubular pathways for blood to pass through and a first-of-its-kind
curved venous inlet tube, both of which can reduce blood turbulence during
the surgical procedure;
* Enhanced setup and customization capabilities, including a new oxygenator
system holder, which gives perfusionists improved flexibility and ease of
use in various operating rooms, including those with limited space.
"The new Affinity Fusion oxygenator is designed to provide perfusionists with
the most innovative and enhanced product of its kind," said cardiac surgeon Dr.
John Liddicoat, senior vice president and president of Medtronic's Structural
Heart division. "With so many patients undergoing cardiac surgery each year,
Affinity Fusion provides patients with a reliable oxygenation system that is
designed to proactively manage air and gently handle blood. This is an
important consideration for hospitals that are focused on implementing patient
blood management programs and other initiatives that can impact costs associated
with transfusions and post-operative complications."
The Fusion oxygenation system was used in the U.S. for the first time at
Cleveland Clinic by perfusionist Patrick Grady, director of Perfusion Services
and a paid member of the expert advisory board for the Fusion, during an open-
heart surgery in which a patient underwent a right mini-thoracotomy and mitral
valve repair procedure. The surgery was performed by Joseph Sabik, M.D., chair
of the Department of Thoracic and Cardiovascular Surgery at Cleveland Clinic and
a paid member of Medtronic's valve scientific advisory board. Additionally, the
Fusion system was used in mitral valve repair cases at The Heart Hospital Baylor
Plano, in Plano, Texas by cardiovascular surgeons Will Ryan, M.D., and Robert
Smith, M.D., with chief perfusionist Al Lione.
The Fusion oxygenation system is used by perfusionists during open-heart
surgical procedures that require a bloodless, motionless surgical field, such as
lifesaving cardiopulmonary bypass surgery. As temporary "lungs," the system adds
oxygen and removes carbon dioxide from the blood. This year, cardiopulmonary
bypass will occur in roughly 1 million patients worldwide. The development
process of the Fusion oxygenator included extensive collaboration between
Medtronic engineers and more than 500 perfusionists worldwide.
The Affinity Fusion oxygenator received CE Mark in September 2012.
In collaboration with leading clinicians, researchers and scientists, Medtronic
offers the broadest range of innovative medical technology for the
interventional and surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services that deliver
clinical and economic value to healthcare consumers and providers worldwide.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global
leader in medical technology - alleviating pain, restoring health, and extending
life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as
those described in Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from anticipated
- end -
 2008 HRI report
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medtronic, Inc. via Thomson Reuters ONE